1. Investigating the inhibition of endoplasmic reticulum α-glucosidase II for the development of broad-spectrum antivirals
- Author
-
Bremner, Fergus Ross and Zitzmann, Nicole
- Abstract
Enveloped viruses hijack the protein production machinery of their host in order to proliferate and their replication/infectivity relies on the correct folding of their surface glycoproteins. This dependence on glycoprotein quality control for viral proliferation makes the host endoplasmic reticulum quality control (ERQC) mechanisms an attractive target for the development of host-targeting antiviral agents, which may show broad-spectrum activity and a high genetic barrier to resistance. A key ERQC protein is α-glucosidase II (GluII), a heterodimeric enzyme bearing a catalytic α-subunit of the GH31 family and an accessory β-subunit that is necessary for full catalytic activity and for the localisation of the heterodimer in the ER. GluII mediates quality control of the folding of nascent glycoproteins by trimming glucose residues from its substrate glycan Glc1-2Man9GlcNAc2. Inhibition of GluII can be achieved using iminosugars which mimic the glucose residue of the native substrate, causing the build-up of misfolded protein in the ER and prevents the secretion of correctly folded glycoproteins. In the case of enveloped virus infection, this inhibits virion secretion or reduces infectivity of secreted virions and has been shown to elicit antiviral effect against a range of enveloped viruses in vitro and in vivo. Iminosugar inhibitors of GluII are effective, but have been associated with significant drug-related adverse effects. In this thesis, I present a novel approach to the inhibition of GluII that involves disruption of the heterodimeric protein-protein interface within the enzyme. Removal of the accessory β subunit from the catalytic α-subunit has been shown to decrease catalytic activity and may induce the export of the catalytic domain out of the ER. Thiopyridones were discovered as small molecules that interfere with the α/β interface and I investigate this protein ligand interaction using techniques such as mass photometry, mass spectrometry and high performance liquid chromatography among others to confirm the capability of these molecules to disrupt the α/β interface and potentially inhibit GluII. Additionally, I outline the design and synthesis of novel iminosugar compounds with the aim of improving the selectivity for GluII relative to existing best-in-class iminosugars. I also use molecular dynamics for in silico examination of the full extent of the GluII α/β interface and the roles of peripheral domains of the β-subunit that are not fully understood based on existing structural data.
- Published
- 2023